Source - LSE Regulatory
RNS Number : 4273O
SkinBioTherapeutics PLC
31 January 2023
 

31 January 2023

SkinBioTherapeutics plc

 

Results of General Meeting

 

SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's General Meeting, held yesterday 30 January 2023, all resolutions were duly passed.

 

Details of the proxy votes received on each resolution by the Company's Registrar are set out below:

 

Resolution

For & Discretionary

Against

Withheld

 

 

Number of votes

%

Number of votes

%

Number of votes

%

1

The Directors' and Auditors' reports and the financial statements for the financial year ended 30 June 2022 be received and adopted

36,364,572

99.58%

117,330

0.32%

37,825

0.10%

2

Jeffreys Henry LLP be re-appointed as the auditors of the Company until the next Annual General Meeting of the Company

36,362,147

99.57%

129,755

0.36%

27,825

0.08%

3

The Directors be authorised to fix the auditors' remuneration

36,377,487

99.61%

114,415

0.31%

27,825

0.08%

4

To authorise the directors to allot shares

36,295,269

99.39%

193,322

0.53%

31,136

0.09%

5

Special resolution to authorise the directors to disapply pre-emption rights

36,257,227

99.28%

232,575

0.64%

29,925

0.08%

6

Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment

36,310,509

99.43%

178,555

0.49%

30,663

0.08%

 

-Ends-

 

 For more information, please contact:

 

SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Manprit Randhawa, CFO

Tel: +44 (0) 191 495 7325

Cenkos Securities Plc (Nominated Adviser & Broker)
Giles Balleny, Max Gould (Corporate Finance)
Dale Bellis, Tamar Cranford-Smith (Sales)

Tel: +44 (0) 20 7397 8900

Instinctif Partners (financial press)
Melanie Toyne-Sewell / Tim Field 

Tel: +44 (0) 20 7457 2020
SkinBioTherapeutics @instinctif.com

 

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFLFLLLIILVIV
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Skinbiotherapeutics PLC (SBTX)

0p (0.00%)
delayed 15:57PM